This year, college welcomes Daniel San Miguel and Adriana Vargus through the BOOT program, providing a generous 12-month stipend plus paid tuition for the first academic year in order to to increase the recruitment, retention and preparation of trainees from diverse backgrounds.
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.
The college was awarded the American Association of Colleges of Pharmacy’s 2020 Lawrence C. Weaver Transformative Community Service Award. This video outlining the community service efforts of the college was included in the virtual ceremony on Wednesday, July 21, 2021 during AACP's annual meeting.
The University of Texas at Austin community members won several Emerging Leaders Spotlight Awards during the recent chapter meeting of the Texas Association of Diversity Officers in Higher Education (TADOHE). The inaugural awards seek to highlight and acknowledge individuals in higher education who actively support TADOHE’s mission and diversity, equity, accessibility and inclusion (DEAI) as a whole.
The UT College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab earned a Texas Global Faculty Research Seed Grant for its work on patient-specific treatment of COVID-19.
Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.
